Unlocking Health Canada's cache of trade secrets: Mandatory disclosure of clinical trial results

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 2, 2012, Pages 194-199

  Herder, Matthew ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CANADA; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; DEVICE APPROVAL; DEVICE SAFETY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GOVERNMENT REGULATION; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; MANDATORY REPORTING; MEDICAL DEVICE;

EID: 84856785086     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110721     Document Type: Article

References (47)

1. Dhalla I, Laupacis A. Moving from opacity to transparency in pharmaceutical policy. CMAJ 2008;178:428-31. (Pubitemid 351303286)
2. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
3. Hébert PC, Stanbrook MB, MacDonald N, et al. Can Health Canada do better in protecting Canadians from unsafe drugs? CMAJ 2011;183:1125-6.
4. Silversides A. Transparency and the drug approval process at Health Canada.Women and Health Protection; 2005.
5. University of British Columbia Therapeutics Initiative. Antidepressant medications in children and adolescents. Therapeutics Letter 2004;52. Available: www.ti.ubc.ca/newsletter/antidepressant-medications-children-and-adolescents (accessed 2011 Aug. 17).
6. Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004;170:1678-86. (Pubitemid 38758745)
7. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
8. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217; discussion e217.
9. Health Canada. Annual report on the administration of the Access to Information Act and the Privacy Act 2000-2001. Ottawa (ON): Health Canada; 2001.
10. Health Canada. Annual reports on the administration of the Access to Information Act and the Privacy Act 2001-2002. Ottawa (ON): Health Canada; 2002.
11. Health Canada. 2004-2005 annual report on the Access to Information Act and the Privacy Act. Ottawa (ON): Health Canada; 2005.
12. Health Canada. Annual report 2005-2006: Access to Information Act and Privacy Act. Ottawa (ON): Health Canada; 2006.
13. Health Canada: Annual report 2006-2007: Access to Information Act and Privacy Act. Ottawa (ON): Health Canada; 2007.
14. Health Canada Access to Information Act annual report 2009-2010. Available: www.hc-sc.gc.ca/ahc-asc/pubs/-atip-aiprp/2010info/index-eng.php (accessed 2011 July 7).
15. Société Gamma Inc. v. Department of the Secretary of State of Canada (1994), 79 F.T.R. 42.
16. AstraZeneca Canada Inc. v. Canada (Health), 2005 FC 1451, aff'd 2006 FCA 241.
17. Canada (Minister of Health) v. Merck Frosst Canada Ltd., 2009 FCA 166 (decision at the Supreme Court of Canada is pending).
18. Memorandum of understanding between the Food and Drug Administration, Department of Health and Human Services of the United States of America and the Health Products and Food Branch, Health Canada, of Canada regarding sharing and exchange of information about therapeutic products. Ottawa (ON): Health Canada; 2009. Available: www.hc-sc.gc.ca/ahc-asc/intactiv /agree-accord/us-eu-sharing- diffusion-eng.php (accessed 2011 July 11).
19. Memorandum of understanding between the Health Products and Food Branch of the Department of Health of Canada and the European Directorate for the Quality of Medicines and Healthcare of the Council of Europe regarding conformity of substances for pharmaceutical use - Health Canada. Ottawa (ON): Health Canada; 2009. Available: www.hc-sc.gc.ca/ahc-asc /intactiv /agree- accord/europe-substances-eng.php (accessed 2011 July 11).
20. Memorandum of understanding between the Health Products and Food Branch - Health Canada - of Canada and the Therapeutic Goods Administration Department of Health and Ageing of Australia regarding therapeutic products. Ottawa (ON): Health Canada; 2009. Available: www.hc-sc.gc.ca/ahc-asc/intactiv/agree-accord/ austral-therap-eng.php (accessed 2011 July 11).
21. North American Free Trade Agreement Between the Government of Canada, the Government of Mexico and the Government of the United States, 17 December 1992, Can. T.S. 1994 No. 2, 32 I.L.M. 289 (entered into force 1 January 1994).
22. WTO Agreement on Trade-Related Aspects of Intellectual Property Rights, 15 April 1994, 33 I.L.M. 1197.
23. Food and Drug Regulations, C.R.C., c. 870, C.08.004.1.
24. MGarity TO. Shapiro SA. The trade secrets status of health and safety testing information: reforming agency disclosure policies. Harv Law Rev 1980;93:837-88.
25. Bayer v. Canada (Attorney General) (1998), 84 C.P.R. (3d) 129 (F.C.).
26. Apotex Inc. v. Canada (Minister of Health) 2010 FCA 334.
27. Opening the medicine cabinet: first report on health aspects of prescription drugs. Report of the Standing Committee on Health Ottawa (ON): House of Commons, Canada; 2004.
28. Herxheimer A, Mintzes B. Antidepressants and adverse effects in young patients: uncovering the evidence. CMAJ 2004;170: 487-9. (Pubitemid 38293644)
29. US Government Accountability Office. Prescription drugs: FDA's oversight of the promotion of drugs for off-label uses. Washington (DC): The Office; 2008. Available: www.gao.gov/products/GAO-08-835 (accessed 2011 July 12).
30. Eisenberg RS. The role of the FDA in innovation policy. Mich Telecom Tech Law Rev 2007;13:345-88.
31. Brief history of drug regulation in Canada. Ottawa (ON): Health Canada; 2007. Available: www.hc-sc.gc.ca/dhp-mps/homologation- licensing/info-renseign/ hist-eng.php (accessed 2011 Aug. 17).
32. Results of the evaluation of phase I of the Summary Basis of Decision project. Ottawa (ON): Health Canada; 2010. Available: www.hc-sc.gc.ca/dhp-mps/ pubs/drug-medic/sbd-er-smd-eng.php (accessed 2011 Aug. 17).
33. Reuters. A time line of Vioxx. The New York Times 2005 Aug. 19. Available: www.nytimes.com/2005/08/19/business/19vioxx.timeline .html (accessed 2011 July 18).
34. Supreme Court of Canada - SCC Case Information - Docket. 33290. Merck Frosst Canada Ltd. v. Minister of Health. Ottawa (ON): Supreme Court of Canada; 2009. Available: www.scc-csc.gc.ca/case-dossier/cms-sgd/dock-regi-eng.aspx?cas= 33290 (accessed 2011 July 18).
35. Office of the Information Commissioner of Canada. Institutions assessed in 2007-2008 and reassessed in 2008-2009: Health Canada. In: 2008-2009 report card at a glance. Ottawa (ON): The Office. Available: www.oic-ci.gc.ca/eng/rp-pr -spe-rep-rap-spe-rep-car-fic-ren-2008-2009-14.aspx (accessed 2011 July 7).
36. Lexchin J. Who's calling the tune: harmonization of drug regulation in Canada. Ottawa (ON): Canadian Centre for Policy Alternatives; 2011. Available: www.policyalternatives.ca/publications/reports/who's-calling-tune (accessed 2011 Aug. 17).
37. Piper ST. The emergence of a medical exception from patentability in the 20th century [thesis]. Oxford (UK): University of Oxford; 2008.
38. Downie J, Herder M. Reflections on the commercialization of research conducted in public institutions in Canada. McGill Health Law Pub 2007;1:23-44.
39. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-9. (Pubitemid 39383201)
40. Graham J, Jones M. Rendre évident : une approche symétrique de la réglementation des produits thérapeutiques. Sociologie et sociétés 2010;42:153-80.
41. McKie D. Too many drugs allowed on market: MP. CBC News 2001 Jan. 20. Available: www.cbc.ca/news/politics/story/2011/01/19/health-canada-drugs.html (accessed 2011 July 15).
42. Schafer A. A bitter pill: safety of drugs is threatened by looser approval process. Ottawa (ON): Canadian Centre for Policy Alternatives; 2011. Available: www.policyalternatives.ca/publications/monitor/bitter-pill (accessed 2011 July 15).
43. Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug promotion: selective reporting of study 329. Int J Risk Saf Med 2008;20:73-81. (Pubitemid 351526054)
44. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med 2004;141:477-8. (Pubitemid 39281885)
45. Krleza-Jeric K, Chan A-W, Dickersin K, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-8. (Pubitemid 40592318)
46. Hirsch L. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors. Curr Med Res Opin 2008;24:1683-9. (Pubitemid 351929066)
47. Silversides A. Withdrawal of clinical trials policy by Canadian research institute is a "lost opportunity for increased transparency."BMJ 2011;342: d2570. doi: 10.1136/bmj.d2570